Corporations are NOT people



















"No one needs an explanation of the power of corporate lobbies in Washington. The Supreme Court's 2010 ruling that affirmed "corporate personhood" — the idea that companies ought to be entitled to basic human rights — broadened their ability to directly contribute to candidates for public office.

In short, unlike average people, businesses now have an even greater chance of buying the laws, regulations and tax loopholes that they want."

-Tom Petruno

The Supreme Court seems to disagree:

http://www.latimes.com/business/la-fi-1119-petruno-markets-20111119,0,6768632.column?page=2
 






Antidepressants are the second most prescribed group of drugs in America. Yet evidence continues to converge on the dangerousness of antidepressant drugs. Given the difficulty showing any effectiveness even in the short-term, the use of these drugs becomes more and more problematic. On top of that, the antidepressants produce serious withdrawal reactions, making it difficult and at times life-threatening to withdraw from them, even with the recommended clinical supervision and slow taper. Psychiatry has always been slow to respond to scientific evidence that its treatments are harmful. Often, as in this case, psychiatry flouts science. The public will have to develop its own resistance to taking antidepressant drugs.

Peter R. Breggin, M.D. is a Harvard-trained psychiatrist and former full-time consultant with NIMH who is in private practice in Ithaca, New York. Dr. Breggin is the author of more than twenty books including the bestseller Talking Back to Prozac and the medical book Brain-Disabling Treatments in Psychiatry, Second Edition. His most recent book is Medication Madness, the Role of Psychiatric Drugs in Cases of Violence, Suicide and Crime. He is also the author of dozens of peer-reviewed scientific articles, many in the field of psychopharmacology. On April 13-15, 2012 in Syracuse, New York, the annual conference of Dr. Breggin's 501c3 nonprofit international organization, The Center for the Study of Empathic Therapy, will present a panel of lawyers, experts, survivors and families concerning antidepressant-induced violence and crime. Conference information is available on
 






Furthermore, Lilly is not doing any real science, and is not a health care company.

Just a revenue stream generator.

Go out and sell.

Well, if Lilly isn't doing any real science, then what generates the revenude stream? Wouldn't it be more accurate to say that Lilly is a revenue stream coordinator?
 






Well, if Lilly isn't doing any real science, then what generates the revenude stream? Wouldn't it be more accurate to say that Lilly is a revenue stream coordinator?

Sure. Generator, coordinator, whatever name you like.

It's a cash cow for Wall Street at this time. "Dividend Aristocrat" as the Motley Fool likes to call it. A darling of moneyed interests.

Show us the innovation!
 






Sure. Generator, coordinator, whatever name you like.

It's a cash cow for Wall Street at this time. "Dividend Aristocrat" as the Motley Fool likes to call it. A darling of moneyed interests.

Show us the innovation!

As a former LRL scientist, I have observed that the science Lilly does is no longer novel industry-leading science. The mentality has changed from searching for first in class (Prozac, Zyprexa) to me-toos that they 'hope' can be best in class or at least viable products (Effient, Livalo, basal insulin currently in Phase 3). So the innovation is of much less impact on society than the Lilly of old. And of particular note, much of the innovation is in-licenced drugs for Lilly and other Big Pharmas. Discovery research in Big Pharma is largely irrelevant at this point.
 






Is this The Church of Scientology posting again? I think you should contact Oprah and voice your concerns to her! I guess I prefer to believe NEJM, JAMA, etc... You fool!
 


















Sure. Generator, coordinator, whatever name you like.

It's a cash cow for Wall Street at this time. "Dividend Aristocrat" as the Motley Fool likes to call it. A darling of moneyed interests.

Show us the innovation!

I think a more correct description of Lilly is as a financial corporation that happens to sell health care products. If you look at the company with that mindset, then everything makes more sense. Our jobs, the management initiatives that are inane from the normal field perspective, etc... it's all to drive the stock price upward. If they could make more money in garbage collection, that is what we would be doing.
 






I think a more correct description of Lilly is as a financial corporation that happens to sell health care products. If you look at the company with that mindset, then everything makes more sense. Our jobs, the management initiatives that are inane from the normal field perspective, etc... it's all to drive the stock price upward. If they could make more money in garbage collection, that is what we would be doing.

Kind of like, "Answers that matter... to Wall Street" ?

Sounds about right. John's statements on the media outlets are dumbed down as much.